Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 07.11.2025 16:15
Latest

1.89 NOK

Change

-0.01

Change (%)

-0.26

Share information

IR contact

News

Reports

Governance

Company presentation

HBC 1
LATEST REPORT

Q2 2025 Financial Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Q2 2025 Financial Report
All reports
OVI 3830 01
NEXT UP

Financial calendar

Quarterly Report Q3
07.11.2025

Quarterly Report Q4
13.02.2026

Stock exchange notices

View all notices

HBC ANNUAL REPORT 2024

11.04.2025

CONTEMPLATING UNSECURED BOND ISSUANCE

10.03.2025

HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP

21.02.2025

PRIMARY INSIDER NOTIFICATION

20.02.2025

FOURTH QUARTER & FULL YEAR 2024 FINANCIAL REPORT

14.02.2025

Contact investor relations

James portrett
James Berger
Chief Commercial Officer
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford portrett
Dr. Crawford Currie
Head of Medical R&D
+44 7968 195497 cc@hofsethbiocare.no